Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])
- PMID: 19932779
- DOI: 10.1016/j.amjcard.2009.07.018
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])
Abstract
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not inferior to the angiotensin-converting enzyme inhibitor ramipril 10 mg, and the combination no more effective than ramipril alone, in decreasing morbidity and mortality in patients with cardiovascular disease or high-risk diabetes. Although therapy targeting angiotensin II is known to decrease left ventricular (LV) mass and volume, the relative influence of angiotensin-converting enzyme inhibitor inhibitors and angiotensin receptor blocker, and their combination, on the heart remains unclear in this population. Magnetic resonance imaging was performed in 287 patients enrolled in ONTARGET, across 8 centers in 6 countries, at randomization and after 2-year treatment (90, 100, and 97 patients in the ramipril, telmisartan, and combination therapy groups, respectively). Baseline patient characteristics showed higher frequencies of coronary artery disease, Asian ethnicity, and use of statins and beta blockers than the main ONTARGET trial. LV mass decreased in all groups (p <0.0001 for each), but there were no significant differences in change in LV mass or volume among groups, except that LV mass index decreased more on combination versus telmisartan (p = 0.04). Key determinants of LV mass decrease were a history of hypertension (p = 0.03), baseline mass (p <0.0001), and decrease in systolic blood pressure (p <0.0001). The best magnetic resonance imaging predictor of composite events was end-systolic volume (p <0.0001). In conclusion, telmisartan and ramipril had similar effects on LV mass and volume, and combination therapy was not more effective, in high-risk patients with cardiovascular disease. These results are consistent with the major outcome findings of the main ONTARGET study.
Similar articles
-
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.Chin Med J (Engl). 2011 Jun;124(12):1763-8. Chin Med J (Engl). 2011. PMID: 21740829 Clinical Trial.
-
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.Am Heart J. 2004 Jul;148(1):52-61. doi: 10.1016/j.ahj.2004.03.020. Am Heart J. 2004. PMID: 15215792 Clinical Trial.
-
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.J Hypertens Suppl. 2009 Jul;27(5):S23-9. doi: 10.1097/01.hjh.0000357905.78704.9a. J Hypertens Suppl. 2009. PMID: 19587551
-
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.Am J Cardiol. 2003 May 22;91(10A):28G-34G. doi: 10.1016/s0002-9149(03)00230-3. Am J Cardiol. 2003. PMID: 12781906 Review.
-
Telmisartan prevents cardiovascular events in a broad group of at-risk patients.Expert Opin Pharmacother. 2009 Dec;10(18):3113-7. doi: 10.1517/14656560903449231. Expert Opin Pharmacother. 2009. PMID: 19925045 Review.
Cited by
-
Telmisartan: a review of its use in cardiovascular disease prevention.Drugs. 2011 Apr 16;71(6):651-77. doi: 10.2165/11206710-000000000-00000. Drugs. 2011. PMID: 21504246 Review.
-
Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction.Regul Pept. 2012 Aug 20;177(1-3):107-15. doi: 10.1016/j.regpep.2012.05.093. Epub 2012 May 14. Regul Pept. 2012. PMID: 22595130 Free PMC article.
-
Management of Hypertension in the Asia-Pacific Region: A Structured Review.Am J Cardiovasc Drugs. 2024 Mar;24(2):141-170. doi: 10.1007/s40256-023-00625-1. Epub 2024 Feb 8. Am J Cardiovasc Drugs. 2024. PMID: 38332411 Free PMC article. Review.
-
Treatment of hypertension in peripheral arterial disease.Cochrane Database Syst Rev. 2013 Dec 4;2013(12):CD003075. doi: 10.1002/14651858.CD003075.pub3. Cochrane Database Syst Rev. 2013. PMID: 24307487 Free PMC article.
-
Left ventricular shape variation in asymptomatic populations: the Multi-Ethnic Study of Atherosclerosis.J Cardiovasc Magn Reson. 2014 Jul 30;16(1):56. doi: 10.1186/s12968-014-0056-2. J Cardiovasc Magn Reson. 2014. PMID: 25160814 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical